| Drug Name |
Dantrolene sodium |
| Drug ID |
BADD_D00577 |
| Description |
Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. |
| Indications and Usage |
For use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. |
| Marketing Status |
approved; investigational |
| ATC Code |
M03CA01 |
| DrugBank ID |
DB01219
|
| KEGG ID |
D02274
|
| MeSH ID |
D003620
|
| PubChem ID |
6604100
|
| TTD Drug ID |
D0I8DD
|
| NDC Product Code |
63629-2169; 0527-3220; 49884-363; 64850-842; 72162-2046; 0904-7211; 0115-4411; 42023-124; 50268-217; 64850-841; 55718-105; 65129-1012; 0115-4433; 72162-2045; 69988-0029; 49884-362; 68084-300; 67262-2000; 0115-4422; 63629-2168; 0527-3219; 71052-508; 55154-7140; 78670-003; 49452-2440; 27505-003; 42023-123; 64850-840; 0527-3221; 10695-140; 69575-4036; 42367-540; 63629-2170; 72162-2047; 49884-364 |
| UNII |
287M0347EV
|
| Synonyms |
Dantrolene | Dantrolene Sodium | Sodium, Dantrolene | Dantrium |
